Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon

Annals of Surgery

Volumn 249, Issue 5, 2009, Pages 814-823

  Nijkamp, Maarten W ^a   Van Der Bilt, Jarmila D W ^a   De Bruijn, Menno T ^a   Molenaar, I Quintus ^a   Voest, Emile E ^a   Van Diest, Paul J ^a   Kranenburg, Onno ^a   Borel Rinkes, Inne H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR INHIBITOR; VATALANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RECURRENCE; CELL DEATH; CELL GROWTH; CELL HYPOXIA; COLORECTAL CANCER; CONTROLLED STUDY; GROWTH INHIBITION; HYPOXEMIA; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; RADIOFREQUENCY ABLATION; RAT; THERMAL INJURY;

ANIMALS; ANOXIA; CATHETER ABLATION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; LIVER; LIVER NEOPLASMS; MALE; MICE; NECROSIS; NEOPLASM RECURRENCE, LOCAL; RATS;

EID: 67649586929     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181a38ef5     Document Type: Article

References (57)

1. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999.
2. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23:2038-2048.
3. Nordlinger B, Van CE, Rougier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer. 2007;43:2037-2045.
4. Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol. 2003;10:338-347.
5. Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007; 246:559-567.
6. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825.
7. Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242:158-171.
8. Mulier S, Ni Y, Jamart J, et al. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol. 2008;15:144-157.
9. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221:159 -166.
10. Ahmad A, Chen SL, Kavanagh MA, et al. Radiofrequency ablation of hepatic metastases from colorectal cancer: are newer generation probes better? Am Surg. 2006;72:875-879.
11. Goldberg SN, Gazelle GS, Compton CC, et al. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer. 2000;88:2452-2463.
12. Isbert C, Roggan A, Ritz JP, et al. Laser-induced thermotherapy: intra- and extralesionary recurrence after incomplete destruction of experimental liver metastasis. Surg Endosc. 2001;15:1320-1326.
13. Hofer SO, Molema G, Hermens RA, et al. The effect of surgical wounding on tumour development. Eur J Surg Oncol. 1999;25:231-243.
14. Svendsen MN, Werther K, Nielsen HJ, et al. VEGF and tumour angiogenesis. Impact of surgery, wound healing, inflammation and blood transfusion. Scand J Gastroenterol. 2002;37:373-379.
15. van der Bilt JD, Borel Rinkes IH. Surgery and angiogenesis. Biochim Biophys Acta. 2004;1654:95-104.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
17. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38-47.
18. van der Bilt JD, Kranenburg O, Nijkamp MW, et al. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology. 2005;42:165-175.
19. van der Bilt JD, Soeters ME, Duyverman AM, et al. Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Am J Pathol. 2007;170:1379-1388.
20. Isaacs JS, Jung YJ, Mimnaugh EG, et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002;277:29936-29944.
21. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002;62:2478-2482.
22. Milkiewicz M, Doyle JL, Fudalewski T, et al. HIF-1alpha and HIF-2alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle. J Physiol. 2007;583:753-766.
23. Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-deme- thoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol. 2002;49:7-19.
24. Hollingshead M, Alley M, Burger AM, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol. 2005;56:115-125.
25. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60:2178-2189.
26. Arteel GE, Thurman RG, Yates JM, et al. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer. 1995;72:889-895.
27. Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the microregional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol. 2003;67:3-15.
28. Katschinski DM, Le L, Heinrich D, et al. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J Biol Chem. 2002;277:9262-9267.
29. Nikfarjam M, Muralidharan V, Christophi C. Altered growth patterns of colorectal liver metastases after thermal ablation. Surgery. 2006;139:73- 81.
30. Ohno T, Kawano K, Yokoyama H, et al. Microwave coagulation therapy accelerates growth of cancer in rat liver. J Hepatol. 2002;36:774 -779.
31. Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008;15:2757-2764.
32. Linnemann U, Schimanski CC, Gebhardt C, et al. Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations. Int J Colorectal Dis. 2004;19:380 -386.
33. Nanko M, Shimada H, Yamaoka H, et al. Micrometastatic colorectal cancer lesions in the liver. Surg Today. 1998;28:707-713.
34. Yokoyama N, Shirai Y, Ajioka Y, et al. Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer. 2002;94:1642- 1647.
35. Minor T, Isselhard W, Berghaus K. Parenchymal and vascular endothelial cell injury in the hypoxic and reperfused rat liver. Evidence for superoxide anion generation by perfusion with ferricytochrome c. Biomed Pharmacother. 1993;47:213-218.
36. Zhou M, Zhang A, Lin B, et al. Study of heat shock response of human umbilical vein endothelial cells (HUVECs) using cDNA microarray. Int J Hyperthermia. 2007;23:225-258.
37. Nikfarjam M, Muralidharan V, Malcontenti-Wilson C, et al. Progressive microvascular injury in liver and colorectal liver metastases following laser induced focal hyperthermia therapy. Lasers Surg Med. 2005;37:64-73.
38. Vaezy S, Martin R, Crum L. High intensity focused ultrasound: a method of hemostasis. Echocardiography. 2001;18:309-315.
39. Kotoh K, Morizono S, Kohjima M, et al. Evaluation of liver parenchymal pressure and portal endothelium damage during radio frequency ablation in an in vivo porcine model. Liver Int. 2005;25:1217-1223.
40. Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology. 2001;221:447-454.
41. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxiamediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485-490.
42. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol. 2003;15:419-424.
43. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003;3:213-217.
44. Beliakoff J, Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs. 2004;15:651-662.
45. Mross K, Drevs J, Muller M, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer. 2005;41:1291-1299.
46. Hecht J, Trabasch T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. 2005;23(pt I of II)(suppl 1):16S. Abstract 3.
47. Kohne C, Bajetta E, Lin E, et al. Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings. 2007;25(pt I)(suppl 20):8S. Abstract 4033.
48. Ahmed M, Liu Z, Lukyanov AN, et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology. 2005;235:469-477.
49. Veenendaal LM, van Hillegersberg R, Smakman N, et al. Synergistic effect of interstitial laser coagulation and doxorubicin in a murine tumor recurrence model of solitary colorectal liver metastasis. Ann Surg Oncol. 2006;13:168-175.
50. Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. Am J Roentgenol. 2002;179:93-101.
51. Denny WA, Wilson WR. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs. 2000;9:2889-2901.
52. Maataoui A, Qian J, Mack MG, et al. Liver metastases in rats: chemoembolization combined with interstitial laser ablation for treatment. Radiology. 2005;237:479-484.
53. Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299:1669-1677.
54. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438: 820-827.
55. Kitamura T, Kometani K, Hashida H, et al. SMAD4-deficient intestinal tumors recruit CCR1 + myeloid cells that promote invasion. Nat Genet. 2007;39:467-475.
56. Isbert C, Boerner A, Ritz JP, et al. In situ ablation of experimental liver metastases delays and reduces residual intrahepatic tumour growth and peritoneal tumour spread compared with hepatic resection. Br J Surg. 2002; 89:1252-1259.
57. Isbert C, Ritz JP, Roggan A, et al. Enhancement of the immune response to residual intrahepatic tumor tissue by LITT compared to hepatic resection. Lasers Surg Med. 2004;35:284-292.